Results 151 to 160 of about 55,779 (204)

Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination. [PDF]

J Infect Dis
Sirivichayakul C, Biswal S, Saez-Llorens X, López-Medina E, Borja-Tabora C, Bravo L, Kosalaraksa P, Alera MT, Reynales H, Rivera L, Watanaveeradej V, Yu D, Espinoza F, Dietze R, Fernando L, Wickramasinghe VP, Moreira ED, Fernando AD, Gunasekera D, Luz K, Venâncio da Cunha R, Oliveira AL, Rauscher M, Fan H, Borkowski A, Escudero I, Tuboi S, Lloyd E, Tricou V, Folschweiller N, LeFevre I, Vargas LM, Wallace D, TIDES Study Group .   +33 more
europepmc   +1 more source

Perceptions of dengue risk and acceptability of a dengue vaccine in residents of Puerto Rico. [PDF]

Hum Vaccin Immunother
Rosado-Santiago C, Pérez-Guerra CL, Vélez-Agosto NM, Colón-Burgos C, Marrero-Santos KM, Partridge SK, Lockwood AE, Young C, Waterman SH, Paz-Bailey G, Cardona-Gerena I, Rivera A, Adams LE, Wong JM.   +13 more
europepmc   +1 more source

An effective pan-serotype dengue vaccine and enhanced control strategies could help in reducing the severe dengue burden in Bangladesh-A perspective. [PDF]

Front Microbiol
Kayesh MEH, Nazneen H, Kohara M, Tsukiyama-Kohara K.   +3 more
europepmc   +1 more source

The N and C-terminal deleted variant of the dengue virus NS1 protein is a potential candidate for dengue vaccine development. [PDF]

Sci Rep
Nasar S, Iftikhar S, Saleem R, Nadeem MS, Ali M.   +4 more
europepmc   +1 more source

Fully automated high-throughput immuno-µPlaque assay for live-attenuated tetravalent dengue vaccine development. [PDF]

Front Immunol
Wang Y, Troutman MC, Hofmann C, Gonzalez A, Song L, Levin R, Pixley HY, Kearns K, DePhillips P, Loughney JW.   +9 more
europepmc   +1 more source

Controlled human infection study underpins efficacy of the tetravalent live-attenuated dengue vaccine TV005. [PDF]

J Clin Invest
Wilder-Smith A.
europepmc   +1 more source

Correction to: Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group. [PDF]

Clin Infect Dis
europepmc   +1 more source

TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies. [PDF]

J Clin Invest
Pierce KK, Durbin AP, Walsh MR, Carmolli M, Sabundayo BP, Dickson DM, Diehl SA, Whitehead SS, Kirkpatrick BD.   +8 more
europepmc   +1 more source

IgG, IgM, and Nonstructural Protein 1 Response Profiles after Receipt of Tetravalent Dengue Vaccine TAK-003 in a Phase 2 Randomized Controlled Trial. [PDF]

Am J Trop Med Hyg
Low JG, Oh HM, Leo YS, Kalimuddin S, Wijaya L, Pang J, Lee TH, Moss KJ, Brose M, Tricou V.   +9 more
europepmc   +1 more source